Healthcare provider profile · identity verified

Edward S Victoria, MD

Allopathic & Osteopathic Physicians|Hospitalist · LAS VEGAS, NV · NPI 1447463500

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Edward S Victoria, MD received $18.74 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$18.74

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$18.74	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$18.74	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$18.74	1	2025
Source payment records 2025-01-30 · Lilly USA, LLC · $18.74 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$18.74	1	2025
Source payment records 2025-01-30 · Lilly USA, LLC · $18.74 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	16 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	42	21
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	19	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	469	191
Amlodipine Besylate	Amlodipine Besylate	323	129
Losartan Potassium	Losartan Potassium	272	117
Levothyroxine Sodium	Levothyroxine Sodium	252	98
Gabapentin	Gabapentin	199	79
Metformin Hcl	Metformin Hcl	199	75
Lisinopril	Lisinopril	157	66
Metoprolol Tartrate	Metoprolol Tartrate	137	71
Tamsulosin Hcl	Tamsulosin Hcl	133	46
Furosemide	Furosemide	120	61
Montelukast Sodium	Montelukast Sodium	110	38
Eliquis	Apixaban	104	40
Pantoprazole Sodium	Pantoprazole Sodium	102	37
Carvedilol	Carvedilol	99	44
Omeprazole	Omeprazole	94	42
Clopidogrel	Clopidogrel Bisulfate	92	54
Trazodone Hcl	Trazodone Hcl	87	31
Hydrochlorothiazide	Hydrochlorothiazide	86	35
Albuterol Sulfate Hfa	Albuterol Sulfate	83	36
Alendronate Sodium	Alendronate Sodium	83	34
Potassium Chloride	Potassium Chloride	75	41
Methocarbamol	Methocarbamol	72	45
Rosuvastatin Calcium	Rosuvastatin Calcium	72	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	69	38
Ozempic	Semaglutide	66	14
Metoprolol Succinate	Metoprolol Succinate	65	34
Simvastatin	Simvastatin	65	26
Allopurinol	Allopurinol	64	26
Ezetimibe	Ezetimibe	61	24
Oxycodone Hcl	Oxycodone Hcl	59	42
Methylprednisolone	Methylprednisolone	56	53
Pravastatin Sodium	Pravastatin Sodium	54	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	53	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	53	18
Ibuprofen	Ibuprofen	50	26
Levetiracetam	Levetiracetam	49	13
Spironolactone	Spironolactone	48	23
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	46	45
Escitalopram Oxalate	Escitalopram Oxalate	45	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	44	28
Zolpidem Tartrate	Zolpidem Tartrate	43	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	22
Hydralazine Hcl	Hydralazine Hcl	42	24
Jardiance	Empagliflozin	42	21
Topiramate	Topiramate	40	suppressed
Azithromycin	Azithromycin	38	34
Duloxetine Hcl	Duloxetine Hcl	38	suppressed
Xarelto	Rivaroxaban	37	14
Amiodarone Hcl	Amiodarone Hcl	34	18
Fluticasone Propionate	Fluticasone Propionate	34	17
Atenolol	Atenolol	30	suppressed
Famotidine	Famotidine	29	18
Fenofibrate	Fenofibrate	29	11
Finasteride	Finasteride	29	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	29	13
Cephalexin	Cephalexin	28	25
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	12
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	28	suppressed
Meclizine Hcl	Meclizine Hcl	27	17
Dicyclomine Hcl	Dicyclomine Hcl	26	11
Ondansetron Odt	Ondansetron	26	14
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Prednisone	Prednisone	26	18
Glipizide	Glipizide	24	13
Meloxicam	Meloxicam	24	13
Novolog Flexpen	Insulin Aspart	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	17
Entresto	Sacubitril/Valsartan	23	suppressed
Telmisartan	Telmisartan	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	11
Baclofen	Baclofen	22	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Valsartan	Valsartan	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Lidocaine	Lidocaine	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	17
Clonidine	Clonidine	19	suppressed
Memantine Hcl	Memantine Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Trulicity	Dulaglutide	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	18	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Diazepam	Diazepam	17	suppressed
Morphine Sulfate Er	Morphine Sulfate	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Mounjaro	Tirzepatide	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Brilinta	Ticagrelor	14	suppressed
Digoxin	Digoxin	14	suppressed
Diltiazem Hcl	Diltiazem Hcl	14	suppressed
Metformin Hcl Er	Metformin Hcl	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Alprazolam	Alprazolam	12	11
Anastrozole	Anastrozole	12	suppressed
Bethanechol Chloride	Bethanechol Chloride	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Minoxidil	Minoxidil	12	suppressed
Primidone	Primidone	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Temazepam	Temazepam	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Nystatin	Nystatin	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$18.74 · 1 records	Lilly USA, LLC	MOUNJARO, ZEPBOUND	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error